Joanne Marie Donovan MD PhD
Associate Clinical Professor of Medicine, Harvard Medical School; Boston VA, VFW Parkway WestRox
Join to View Full Profile
150 South Huntington AvenueBoston, MA 02130
Phone+1 617-323-7700
Dr. Donovan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's HospitalFellowship, Gastroenterology, 1989 - 1990- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1984 - 1987
Harvard Medical SchoolClass of 1984
Certifications & Licensure
MA State Medical License 1986 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
Publications & Presentations
PubMed
- Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexentMaria Cecilia Mancini, Gigi Shafai, Elizabeth Thaler, Joanne M. Donovan, Richard S. Finkel
Journal of Clinical Pharmacy and Therapeutics. 2021-07-14 - 19 citationsDisease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension...Richard S. Finkel, Erika Finanger, Krista Vandenborne, H. Lee Sweeney, Gihan Tennekoon
Neuromuscular Disorders. 2021-02-04 - 18 citationsA Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD...Richard S. Finkel, Craig M. McDonald, H. Lee Sweeney, Erika Finanger, Erin Neil Knierbein
Journal of Neuromuscular Diseases. 2021-01-01
Press Mentions
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)October 28th, 2022- EDG-5506 Shows Promise at Reducing Becker MD Muscle DamageOctober 20th, 2022
- EDG-5506 Shows Promise at Reducing Becker MD Muscle DamageOctober 20th, 2022
- Join now to see all
Grant Support
- Pilot Study--Mechanisms Of Cytoprotection By Hydrophilic Bile SaltsNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
